Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) plans to
conduct additional clinical trials using DehydraTECH(TM) in CBD after recently
reporting noteworthy results of cardiovascular performance improvements with
TurboCBD. A recent article discussing the company reads, “TurboCBD is Lexaria’s
proprietary DehydraTECH-powered, CBD-fortified hemp-oil capsule. The capsules
are formulated with full-spectrum hemp oil, ginseng and ginkgo for enhanced
focus and memory. They are marketed as a mental and physical boost aimed at
helping to remove brain fog, fatigue and stress. TurboCBD is molecularly
engineered for quick and high absorption rates into the circulatory system. . .
. In a recent press release (http://ibn.fm/OwOtT),
Lexaria announced that the results from a healthy-human clinical trial provided
evidence that a single 90mg dose of TurboCBD resulted in lower blood pressure,
higher blood flow to the brain, faster delivery onset of CBD into the
bloodstream and larger quantities of CBD within the blood as compared to an
equal dose of generic CBD. Due to the positive results of this study, the
company plans to conduct additional human clinical trials over the course of
the next year using DehydraTECH in CBD.”
To view the full article, visit http://ibn.fm/1EGED
About Lexaria Bioscience Corp.
Lexaria Bioscience has developed and outlicenses its
disruptive delivery technology that promotes healthier ingestion methods, lower
overall dosing and quicker onset of lipophilic active molecules. Lexaria has 10
patents granted in the United States and Australia, and has filed over 50
patent applications worldwide across 10 patent families. Lexaria’s technology
provides more rapid delivery to the bloodstream, as well as important
taste-masking benefits for orally administered bioactive molecules including
cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine
and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
